MAP3K5 and metabolic dysfunction-associated steatohepatitis: Selonsertib is a first-in-class inhibitor of ASK1 that has been shown to prevent inflammation, fibrosis, excessive apoptosis and progression to cirrhosis in a Phase II clinical trial in patients with NASH and stage 2-3 fibrosis (114).